バイオサージェリーの世界市場：洞察、競合情勢、市場予測：2030年

世界のバイオサージェリーの市場規模は、2024年～2030年の予測期間中に9.23％のCAGRで拡大すると予測されています。バイオサージェリー市場は、心血管疾患の罹患率の上昇、整形手術の需要の増加、前立腺がんなどの、がんの罹患率の上昇、バイオサージェリー製品の市場投入の急増など、様々な要因によりプラスの成長が促進されています。

心血管疾患の増加とともに、バイオサージェリーの需要も増加しています。例えば、英国心臓財団が2023年に発表した最新データによると、2019年、アジアでは、32,376,834人が心血管疾患に罹患し、12,543,833人が冠動脈疾患と診断され、8,111,044人が脳卒中と検出されました。このように、バイオサージェリー製品は、安全で効果的で、出血を防ぎ、手術後の創傷治癒を促進するため、心臓血管外科手術の際に使用されています。

さらに、バイオサージェリー市場の成長をもたらしているもう1つの重要な要因は、整形手術の需要の増加です。例えば、2020年に発表された最新の形成外科統計報告書によると、アメリカでは美容整形手術1,560万件のうち、230万件が美容外科手術であったのに対し、1,320万件が低侵襲手術でした。上記の情報源によると、2020年の再建手術は680万件（2019年比3％増）でした。このように、整形手術の需要が増加することで、バイオサージェリーの需要を押し上げることができ、ひいては市場全体に成長環境を提供することができます。

当レポートでは、世界のバイオサージェリー市場について調査し、市場の概要とともに、製品タイプ別、用途別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 バイオサージェリー市場レポートのイントロダクション

第2章 バイオサーエグゼクティブサマリー

第3章 規制分析

• 米国
• 欧州
• 日本
• 中国

第4章 バイオサージェリー市場の主な要因分析

• バイオサージェリー市場の促進要因
• バイオサージェリー市場の抑制要因と課題
• バイオサージェリー市場の機会

第5章 バイオサージェリー市場におけるポーターのファイブフォース分析

第6章 バイオサージェリー市場に対するCOVID-19の影響分析

第7章 バイオサージェリー市場の概要

• 製品タイプ別
• 用途別
• エンドユーザー別
• 地域別

第8章 バイオサージェリー市場の世界企業シェア分析-主要3～5社

第9章 バイオサージェリー市場の企業と製品プロファイル

• BD
• Baxter
• SAMYANG HOLDING CORPORATION
• B. Braun Melsungen AG
• Stryker
• Integra LifeSciences
• Hemostasis LLC
• Biom'Up
• Pfizer Inc
• Ethicon US LLC (Johnson & Johnson Services Inc)
• CryoLife Inc
• Zimmer Biomet
• Kuros Biosciences
• Orthofix US LLC
• Tissue Regenix
• Betatech Medical
• Meril Life Sciences Pvt. Ltd
• RTI Surgical
• AROA BIOSURGERY LIMITED
• BioCer Entwicklungs-GmbH

第10章 KOL の見解

第11章 プロジェクトのアプローチ

第12章 DelveInsightについて

第13章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: COVID-19 Impact Analysis
• Table 3: Biosurgery Market in Global (2021-2030)
• Table 4: Biosurgery Market in Global by Product Type (2021-2030)
• Table 5: Biosurgery Market in Global by Application (2021-2030)
• Table 6: Biosurgery Market in Global by End-User (2021-2030)
• Table 7: Biosurgery Market in Global by Geography (2021-2030)
• Table 8: Biosurgery Market in North America (2021-2030)
• Table 9: Biosurgery Market in North America by Country (2021-2030)
• Table 10: Biosurgery Market in the US (2021-2030)
• Table 11: Biosurgery Market in Canada (2021-2030)
• Table 12: Biosurgery Market in Mexico (2021-2030)
• Table 13: Biosurgery Market in Europe (2021-2030)
• Table 14: Biosurgery Market in Europe by Country (2021-2030)
• Table 15: Biosurgery Market in France (2021-2030)
• Table 16: Biosurgery Market in Germany (2021-2030)
• Table 17: Biosurgery Market in the United Kingdom (2021-2030)
• Table 18: Biosurgery Market in Italy (2021-2030)
• Table 19: Biosurgery Market in Spain (2021-2030)
• Table 20: Biosurgery Market in Russia (2021-2030)
• Table 21: Biosurgery Market in Rest of Europe (2021-2030)
• Table 22: Biosurgery Market in APAC (2021-2030)
• Table 23: Biosurgery Market in APAC by Country (2021-2030)
• Table 24: Biosurgery Market in China (2021-2030)
• Table 25: Biosurgery Market in Japan (2021-2030)
• Table 26: Biosurgery Market in India (2021-2030)
• Table 27: Biosurgery Market in Australia (2021-2030)
• Table 28: Biosurgery Market in South Korea (2021-2030)
• Table 29: Biosurgery Market in Rest of APAC (2021-2030)
• Table 30: Biosurgery Market in Rest of World (2021-2030)
• Table 31: Biosurgery Market in RoW by Region (2021-2030)
• Table 32: Biosurgery Market in Middle East (2021-2030)
• Table 33: Biosurgery Market in Africa (2021-2030)
• Table 34: Biosurgery Market in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: COVID-19 Impact Analysis
• Figure 3: Biosurgery Market in Global (2021-2030)
• Figure 4: Biosurgery Market in Global by Product Type (2021-2030)
• Figure 5: Biosurgery Market in Global by Application (2021-2030)
• Figure 6: Biosurgery Market in Global by End-User (2021-2030)
• Figure 7: Biosurgery Market in Global by Geography (2021-2030)
• Figure 8: Biosurgery Market in North America (2021-2030)
• Figure 9: Biosurgery Market in North America by Country (2021-2030)
• Figure 10: Biosurgery Market in the US (2021-2030)
• Figure 11: Biosurgery Market in Canada (2021-2030)
• Figure 12: Biosurgery Market in Mexico (2021-2030)
• Figure 13: Biosurgery Market in Europe (2021-2030)
• Figure 14: Biosurgery Market in Europe by Country (2021-2030)
• Figure 15: Biosurgery Market in France (2021-2030)
• Figure 16: Biosurgery Market in Germany (2021-2030)
• Figure 17: Biosurgery Market in the United Kingdom (2021-2030)
• Figure 18: Biosurgery Market in Italy (2021-2030)
• Figure 19: Biosurgery Market in Spain (2021-2030)
• Figure 20: Biosurgery Market in Russia (2021-2030)
• Figure 21: Biosurgery Market in Rest of Europe (2021-2030)
• Figure 22: Biosurgery Market in APAC (2021-2030)
• Figure 23: Biosurgery Market in APAC by Country (2021-2030)
• Figure 24: Biosurgery Market in China (2021-2030)
• Figure 25: Biosurgery Market in Japan (2021-2030)
• Figure 26: Biosurgery Market in India (2021-2030)
• Figure 27: Biosurgery Market in Australia (2021-2030)
• Figure 28: Biosurgery Market in South Korea (2021-2030)
• Figure 29: Biosurgery Market in Rest of APAC (2021-2030)
• Figure 30: Biosurgery Market in Rest of World (2021-2030)
• Figure 31: Biosurgery Market in RoW by Region (2021-2030)
• Figure 32: Biosurgery Market in the Middle East (2021-2030)
• Figure 33: Biosurgery Market in Africa (2021-2030)
• Figure 34: Biosurgery Market in South America (2021-2030)
• Figure 35: Market Drivers
• Figure 36: Market Barriers
• Figure 37: Marker Opportunities
• Figure 38: PORTER'S Five Force Analysis

Biosurgery Market By Product Type (Sealant, Haemostat, Bone Graft Substitute, Adhesion Barriers, And Others), By Application (Cardiovascular Surgery, General Surgery, Plastic Surgery, Orthopedic Surgery, And Others), By End-User (Hospitals And Ambulatory Surgical Centers), and by geography is expected to grow at a steady CAGR forecast till 2030 owing to the increasing demand of plastic surgery and increasing incidence of cardiovascular diseases

The global biosurgery market can be anticipated to grow at a CAGR of 9.23% during the forecast period of 2024-2030. The biosurgery market is witnessing a positive growth owing to various factors such as the increasing incidence of cardiovascular diseases, increasing demand of plastic surgery, the increasing incidence of cancers such as prostate cancer and surge in the biosurgery products launch in the market. Therefore, the market for biosurgery is estimated to grow during the forecast period from 2024 to 2030.

Biosurgery Market Dynamics:

As with the increasing incidence of cardiovascular diseases, the demand for biosurgery also increases. For instance, according to the latest data published by the British Heart Foundation in the year 2023, in 2019, in Asia, 32,376,834 people were affected with cardiovascular diseases, 12,543,833 individuals were diagnosed with coronary artery disease, and 8,111,044 population was detected with stroke. Thus, biosurgery products are used during the cardiovascular surgery, as they are safe, effective, prevent bleeding and initiate wound healing after the surgery. Therefore, the increasing incidence of cardiovascular diseases, can boost the demand of biosurgery, which could drive the overall biosurgery market forward over the forecast period (2024-2030).

Moreover, another key factor which is responsible for the growth of biosurgery market is the increasing demand of plastic surgery. For instance, according to the latest plastic surgery statistics report published in the year 2020, in America, out of 15.6 million of cosmetic operations, 2.3 million were cosmetic surgical procedures whereas 13.2 million cosmetic were minimally-invasive procedures. According to the source mentioned above, in 2020, reconstructive procedures were 6.8 Million (3% increase from 2019). Thus, increasing demand of plastic surgery, could boost the demand for biosurgery which in turn can provide a conductive growth environment for the biosurgery overall market.

Therefore, due to the aforementioned factors, biosurgery demand increases, which will surge the growth of the overall biosurgery market during the forecast period from 2024 to 2030.

However, rising cost of surgical procedures and complications related to surgical procedures such as infection, pain and others, this can hamper the global biosurgery market growth.

Additionally, the ongoing COVID-19 pandemic has significantly impacted the biosurgery market. There was a nationwide lockdown in almost every country, movement restrictions declined the number of hospital visits for elective surgeries and unavailability of the workforce at the production sites hampered the manufacturing rate of biosurgery products. However, due to spread of infection in the lungs by covid virus, it increased the demand of lung surgeries. Meanwhile, other elective surgeries were not given priority because COVID-19 patients were preferred more in terms of treatment. Moreover, according to the American Hospital Association 2020, between March and June 2020, hospitals in the United States lost an estimated USD 50.7 billion due to a decrease in "elective" treatments. According to the same research, these processes accounted for around 31% of net revenue in the United States on an average. However, with the masses being vaccinated, relaxation in the lockdown restrictions & the hospital visits of patients for elective surgeries as well as resumption of supply chains, logistics, and manufacturing units, the biosurgery can be expected to further grow during the forecast period.

Biosurgery Market Segment Analysis:

Biosurgery Market by Product Type (Sealant, Hemostat, Bone Graft Substitute, Adhesion Barriers, and Others), Application (Cardiovascular Surgery, General Surgery, Plastic Surgery, Orthopedic Surgery and Others), End-User (Hospitals and Ambulatory Surgical Centers), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the by-product type segment of the biosurgery market, hemostat is expected to hold a significant revenue share in the year 2023. The key attributes driving the growth of the biosurgery market includes, hemostats are developed to clamp small blood vessels for hemorrhage control, it is used to grasp & secure superficial fascia during undermining and debriding wounds. Moreover, this instrument is an excellent tool for exposing, exploring, and visualizing the deeper areas of a wound, hemostatic agent helps in the propagation of a more stable clot that is less prone to rupture during the moment of the casualty.

Furthermore, the key benefits associated with hemostats can increase the demand for biosurgery, which could drive the growth of the overall global biosurgery market during the forecast period. However, technological advancement and commercialization of biosurgery products also drives the market growth.

In July 2022, Medcura Inc, a medical device company, in partnership with ASO, LLC, a major U.S. manufacturer and supplier of first aid products, announced the launch of a high-performance, antibacterial hemostatic gel, Rapid-Seal®. It can be easily applied for irregular injuries where bandages could be inconvenient, as well as powders are messy & can cause discomfort.

In March 2020, Ethicon US LLC, a subsidiary of Johnson & Johnson Services Inc, announced the launch of SURGICEL® POWDER ABSORBABLE HEMOSTAT in Australia, New Zealand, as well as in Thailand. It is currently accessible in Singapore and Hong Kong. This development is a powdered adjunctive hemostat that aims to improve the effectiveness of disruptive bleeding control for surgeons.

Moreover, due to the interplay of the aforementioned factors, this can result in the rising demand for biosurgery, which in turn would provide a conducive growth environment for overall biosurgery market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall Biosurgery Market:

Among all the regions, North America is expected to dominate the global biosurgery market in the year 2023 and is expected to do the same during the forecast period from 2024 to 2030. Factors such as the increasing incidence of cancers such as prostate cancer and surge in the biosurgery products launch in the market are expected to increase the demand for biosurgery in the North America market.

According to the latest data published by American Cancer Society, Inc. in the year 2023, it is estimated that in the year 2023, in United States, there will be 268,490 new cases of prostate cancer. Moreover, biosurgery products could be used to remove the prostate gland, as they are safe, effective, prevent bleeding and initiate wound healing after the surgery. Therefore, the increasing incidence of cancers such as prostate cancer, can boost the demand of biosurgery, which could drive the overall biosurgery market forward over the forecast period (2024-2030).

Furthermore, another factor that is responsible for the growth of biosurgery market is the surge in the biosurgery products launch in the market. For instance, in April 2022, Aroa Biosurgery, a soft tissue regeneration company, launched a new product named Myriad Morcells(TM), a morcellized (powder) format of Myriad Matrix(TM) which easily conforms to maximise interaction with uneven wound beds. Myriad Matrix(TM) is used during the surgical treatment of hidradenitis suppurativa, complex wounds and exposed vital structures.

In February 2020, Aroa Biosurgery, the Auckland-based privately held soft-tissue repair company, launched a large format version of its Endoform® Natural product in United States and Canadian markets, following its recent approval for reimbursement within the U.S. healthcare system. It is used to treat large surgical wounds with a single sheet of their extracellular matrix-based product.

Therefore, due to interplay of the factors mentioned above, there will be a higher demand for biosurgery, which would provide a conducive growth environment for the North American region in the biosurgery market.

Biosurgery Market Key Players:

Some of the key market players operating in the Biosurgery market include BD, Baxter, SAMYANG HOLDING CORPORATION, B. Braun Melsungen AG, Stryker, Integra LifeSciences, Hemostasis LLC, Biom'Up, Pfizer Inc, Ethicon US LLC (Johnson & Johnson Services Inc), CryoLife Inc, Zimmer Biomet, Kuros Biosciences, Orthofix US LLC, Tissue Regenix, Betatech Medical, Meril Life Sciences Pvt. Ltd, RTI Surgical, AROA BIOSURGERY LIMITED, BioCer Entwicklungs-GmbH, among others

Recent Developmental Activities in the Biosurgery:

In February 2022, Gunze Limited, announced that it has received medical device approval to manufacture and sell TENALEAF(TM), the first sheet-type absorbable adhesion barrier made in Japan. During open surgery and minimally invasive surgery, this device gives surgeons a new choice that can facilitate simple manipulation, provide a modest amount of adhesive strength for repositioning, and allow for conformable insertion.

In December 2022, BD, a global medical technology company, announced that it has acquired Tissuemed, Ltd., a privately held company which has headquarter in Leeds, England it is an industry leader in developing self-adhesive surgical sealant films. Tissuemed's lead product, Tissuepatch(TM), is a proprietary sealant technology that bonds to tissue to help control internal bleeding or stop leakage from surgical wounds.

In February 2022, Baxter International Inc, a leading global medical products company, announced acquisition of Seprafilm Adhesion Barrier which is used as an adjunct to limit the incidence, extent & severity of adhesions in certain pelvic and abdominal surgeries.

Key Takeaways from the Biosurgery Market Report Study:

• Market size analysis for current biosurgery market (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the biosurgery market
• Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years
• Key companies dominating the global biosurgery market.
• Various opportunities are available for the other competitor in the biosurgery market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030.
• Which are the top-performing regions and countries in the current biosurgery market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for biosurgery market growth in the coming future?

Target Audience who can be benefited from this Biosurgery Market Report Study:

• Biosurgery providers
• Research organizations and consulting companies
• Biosurgery-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in biosurgery
• Various end-users who want to know more about the biosurgery market and latest technological developments in the biosurgery

Frequently Asked Questions for Biosurgery:

1. What is Biosurgery?

Biosurgery products are designed to reduce bleeding during various operations and to speed wound and surgical site healing. Due to their many benefits, including their efficacy, usability, and safety in various circumstances, these items are chosen in addition to conventional procedures (such as staples and sutures) for wound closure.

2. What is the market for Global Biosurgery?

The global biosurgery market can be anticipated to grow at a CAGR of 9.23% during the forecast period of 2024-2030.

3. What are the drivers for the Global Biosurgery market?

The biosurgery market is witnessing a positive market growth owing to the factors such as the increasing incidence of cardiovascular diseases, increasing demand of plastic surgery, the increasing incidence of cancers such as prostate cancer and surge in the biosurgery products launch in the market.

4. Who are the key players operating in the Biosurgery market?

Some of the key market players operating in the biosurgery market include BD, Baxter, SAMYANG HOLDING CORPORATION, B. Braun Melsungen AG, Stryker, Integra LifeSciences, Hemostasis LLC, Biom'Up, Pfizer Inc, Ethicon US LLC (Johnson & Johnson Services Inc), CryoLife Inc, Zimmer Biomet, Kuros Biosciences, Orthofix US LLC, Tissue Regenix, Betatech Medical, Meril Life Sciences Pvt. Ltd, RTI Surgical, AROA BIOSURGERY LIMITED, BioCer Entwicklungs-GmbH.

5. Which region has the highest share in Biosurgery Market?

North America is expected to dominate the global biosurgery market. Factors contributing to the growth of biosurgery market in the North America region are the increasing incidence of cancers such as prostate cancer and surge in the biosurgery products launch in the market.

Table of Contents

1.Biosurgery Market Report Introduction

2.Biosurgery Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment
• 2.4. Financial Benchmarking

3. Regulatory Analysis

• 3.1. The US
• 3.2. Europe
• 3.3. Japan
• 3.4. China

4. Biosurgery Market Key Factors Analysis

• 4.1. Biosurgery Market Drivers
  • 4.1.1. The Increasing Incidence of Cardiovascular Diseases
  • 4.1.2. Increasing Demand of Plastic Surgery
  • 4.1.3. The Increasing Incidence of Cancers such as Prostate Cancer
  • 4.1.4. Surge in the Biosurgery Products Launch in the Market
• 4.2. Biosurgery Market Restraints And Challenges
  • 4.2.1. Rising Cost of Surgical Procedures
  • 4.2.2. Complications Related to Surgical Procedures such as Infection, Pain and Others
• 4.3. Biosurgery Market Opportunities
  • 4.3.1. Increasing Research and Development Activities in Biosurgery
  • 4.3.2. Rising Healthcare Awareness

5. Biosurgery Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Biosurgery Market

7. Biosurgery Market Layout

• 7.1. By Product Type
  • 7.1.1. Sealant
  • 7.1.2. Hemostat
  • 7.1.3. Bone Graft Substitute
  • 7.1.4. Adhesion Barriers
  • 7.1.5. Others
• 7.2. By Application
  • 7.2.1. Cardiovascular Surgery
  • 7.2.2. General Surgery
  • 7.2.4. Plastic Surgery
  • 7.2.4. Orthopedic Surgery
  • 7.2.5. Others
• 7.3. By End User
  • 7.3.1. Hospitals
  • 7.3.2. Ambulatory Surgical Centers
• 7.4. By Geography
  • 7.4.1. North America
    • 7.4.1.1. United States Biosurgery Market Size in USD Million (2021-2030)
    • 7.4.1.2. Canada Biosurgery Market Size in USD Million (2021-2030)
    • 7.4.1.3. Mexico Biosurgery Market Size in USD Million (2021-2030)
  • 7.4.2. Europe
    • 7.4.2.1. France Biosurgery Market Size in USD Million (2021-2030)
    • 7.4.2.2. Germany Biosurgery Market Size in USD Million (2021-2030)
    • 7.4.2.3. United Kingdom Biosurgery Market Size in USD Million (2021-2030)
    • 7.4.2.4. Italy Biosurgery Market Size in USD Million (2021-2030)
    • 7.4.2.5. Spain Biosurgery Market Size in USD Million (2021-2030)
    • 7.4.2.6. Russia Biosurgery Market Size in USD Million (2021-2030)
    • 7.4.2.7. Rest of Europe Biosurgery Market Size in USD Million (2021-2030)
  • 7.4.3. Asia-Pacific
    • 7.4.3.1. China Biosurgery Market Size in USD Million (2021-2030)
    • 7.4.3.2. Japan Biosurgery Market Size in USD Million (2021-2030)
    • 7.4.3.3. India Biosurgery Market Size in USD Million (2021-2030)
    • 7.4.3.4. Australia Biosurgery Market Size in USD Million (2021-2030)
    • 7.4.3.5. South Korea Biosurgery Market Size in USD Million (2021-2030)
    • 7.4.3.6. Rest of Asia Pacific Biosurgery Market Size in USD Million (2021-2030)
  • 7.4.4. Rest of the World (RoW)
    • 7.4.4.1. Middle East Biosurgery Market Size in USD Million (2021-2030)
    • 7.4.4.2. Africa Biosurgery Market Size in USD Million (2021-2030)
    • 7.4.4.3. South America Biosurgery Market Size in USD Million (2021-2030)

8. Biosurgery Market Global Company Share Analysis - Key 3-5 Companies

9. Biosurgery Market Company and Product Profiles

• 9.1. BD
  • 9.1.1. Company Overview
  • 9.1.2. Company Snapshot
  • 9.1.3. Financial Overview
  • 9.1.4. Product Listing
  • 9.1.5. Entropy
• 9.2. Baxter
  • 9.2.1. Company Overview
  • 9.2.2. Company Snapshot
  • 9.2.3. Financial Overview
  • 9.2.4. Product Listing
  • 9.2.5. Entropy
• 9.3. SAMYANG HOLDING CORPORATION
  • 9.3.1. Company Overview
  • 9.3.2. Company Snapshot
  • 9.3.3. Financial Overview
  • 9.3.4. Product Listing
  • 9.3.5. Entropy
• 9.4. B. Braun Melsungen AG
  • 9.4.1. Company Overview
  • 9.4.2. Company Snapshot
  • 9.4.3. Financial Overview
  • 9.4.4. Product Listing
  • 9.4.5. Entropy
• 9.5. Stryker
  • 9.5.1. Company Overview
  • 9.5.2. Company Snapshot
  • 9.5.3. Financial Overview
  • 9.5.4. Product Listing
  • 9.5.5. Entropy
• 9.6. Integra LifeSciences
  • 9.6.1. Company Overview
  • 9.6.2. Company Snapshot
  • 9.6.3. Financial Overview
  • 9.6.4. Product Listing
  • 9.6.5. Entropy
• 9.7. Hemostasis LLC
  • 9.7.1. Company Overview
  • 9.7.2. Company Snapshot
  • 9.7.3. Financial Overview
  • 9.7.4. Product Listing
  • 9.7.5. Entropy
• 9.8. Biom'Up
  • 9.8.1. Company Overview
  • 9.8.2. Company Snapshot
  • 9.8.3. Financial Overview
  • 9.8.4. Product Listing
  • 9.8.5. Entropy
• 9.9. Pfizer Inc
  • 9.9.1. Company Overview
  • 9.9.2. Company Snapshot
  • 9.9.3. Financial Overview
  • 9.9.4. Product Listing
  • 9.9.5. Entropy
• 9.10. Ethicon US LLC (Johnson & Johnson Services Inc)
  • 9.10.1. Company Overview
  • 9.10.2. Company Snapshot
  • 9.10.3. Financial Overview
  • 9.10.4. Product Listing
  • 9.10.5. Entropy
• 9.11. CryoLife Inc
  • 9.11.1. Company Overview
  • 9.11.2. Company Snapshot
  • 9.11.3. Financial Overview
  • 9.11.4. Product Listing
  • 9.11.5. Entropy
• 9.12. Zimmer Biomet
  • 9.12.1. Company Overview
  • 9.12.2. Company Snapshot
  • 9.12.3. Financial Overview
  • 9.12.4. Product Listing
  • 9.12.5. Entropy
• 9.13. Kuros Biosciences
  • 9.13.1. Company Overview
  • 9.13.2. Company Snapshot
  • 9.13.3. Financial Overview
  • 9.13.4. Product Listing
  • 9.13.5. Entropy
• 9.14. Orthofix US LLC
  • 9.14.1. Company Overview
  • 9.14.2. Company Snapshot
  • 9.14.3. Financial Overview
  • 9.14.4. Product Listing
  • 9.14.5. Entropy
• 9.15. Tissue Regenix
  • 9.15.1. Company Overview
  • 9.15.2. Company Snapshot
  • 9.15.3. Financial Overview
  • 9.15.4. Product Listing
  • 9.15.5. Entropy
• 9.16. Betatech Medical
  • 9.16.1. Company Overview
  • 9.16.2. Company Snapshot
  • 9.16.3. Financial Overview
  • 9.16.4. Product Listing
  • 9.16.5. Entropy
• 9.17. Meril Life Sciences Pvt. Ltd
  • 9.17.1. Company Overview
  • 9.17.2. Company Snapshot
  • 9.17.3. Financial Overview
  • 9.17.4. Product Listing
  • 9.17.5. Entropy
• 9.18. RTI Surgical
  • 9.18.1. Company Overview
  • 9.18.2. Company Snapshot
  • 9.18.3. Financial Overview
  • 9.18.4. Product Listing
  • 9.18.5. Entropy
• 9.19. AROA BIOSURGERY LIMITED
  • 9.19.1. Company Overview
  • 9.19.2. Company Snapshot
  • 9.19.3. Financial Overview
  • 9.19.4. Product Listing
  • 9.19.5. Entropy
• 9.20. BioCer Entwicklungs-GmbH
  • 9.20.1. Company Overview
  • 9.20.2. Company Snapshot
  • 9.20.3. Financial Overview
  • 9.20.4. Product Listing
  • 9.20.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us